Clinical trial · Observational
ALDH1A1 Expression in Invasive Mammary Carcinoma
ALDH1A1 as A Stem Cell Marker and Its Correlation With the Clinico-pathological Parameters in Invasive Mammary Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
ALDH1A1 isozyme oxidizes Retinaldehyde to retinoic acid, which regulates the expression of the genes involved in tumor-initiating stem-like cells, thereby initiating tumor growth and resistance to drugs. Much emphasis has been focused on ALDH1A1 as a CSC marker. High expression of ALDH1A1 has been reported as a poor prognostic marker in several tumor types and is associated with poor patient outcomes .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- evaluate expression of ALDH1A1 in invasive mammary carcinoma
- timeFrame
- 4 month
- description
- immunohistochemical study
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Patients with invasive mammary carcinoma carcinoma and underwent surgery Exclusion Criteria: * Cases received pre-operative chemotherapy or radiotherapy. * Cases with insufficient clinical data.
References
Publications (0)
Data not yet available